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Abstract
The capacity to integrate transgenes into the host cell genome makes retroviral vectors an
interesting tool for gene therapy. Although stable insertion resulted in successful correction
of several monogenic disorders, it also accounts for insertional mutagenesis, a major set-
back in otherwise successful clinical gene therapy trials due to leukemia development in a
subset of treated patients. Despite improvements in vector design, their use is still not risk-
free. Lentiviral vector (LV) integration is directed into active transcription units by LEDGF/
p75, a host-cell protein co-opted by the viral integrase. We engineered LEDGF/p75-based
hybrid tethers in an effort to elicit a more random integration pattern to increase biosafety,
and potentially reduce proto-oncogene activation. We therefore truncated LEDGF/p75
by deleting the N-terminal chromatin-reading PWWP-domain, and replaced this domain
with alternative pan-chromatin binding peptides. Expression of these LEDGF-hybrids in
LEDGF-depleted cells efficiently rescued LV transduction and resulted in LV integrations
that distributed more randomly throughout the host-cell genome. In addition, when consid-
ering safe harbor criteria, LV integration sites for these LEDGF-hybrids distributed more
safely compared to LEDGF/p75-mediated integration in wild-type cells. This approach
should be broadly applicable to introduce therapeutic or suicide genes for cell therapy,
such as patient-specific iPS cells.
Introduction
The capacity to integrate transgenes into the host cell genome makes retroviral vectors (RV) an
interesting tool for gene therapeutic applications as stable insertion of transgenes into the
genome ensures long-term expression. Use of RV-mediated gene transfer resulted in successful
cure of several monogenic, primary immunodeficiencydisorders [1–3]. Yet, stable insertion
occasionally altered endogenous gene regulation resulting in insertionalmutagenesis. Due to
this major setback 5 out of 19 treated patients developed leukemia in otherwise successful clini-
cal gene therapy trials for X-SCID and 2 out of 2 patients treated for X-CGD acquiredmyelo-
dysplastic syndrome [3–6]. Both trials employed murine leukemia virus (MLV)-based
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gammaretroviral vectors (γRV) that integrate in close proximity to gene regulatory regions [7–
9] and resulted in transcriptional deregulation due to up-regulated LMO2 expression [10–13].
Similar reports on insertionalmutagenesis were published after integration of γRV near
CCDN2,BMI1 and EVI1 [14,15]. Despite improvements in vector design (e.g. self-inactivating
(SIN) vectors) their use is still not risk-free [3,4,6,14–16], which shifted attention from yRV
towards HIV-derived lentiviral vectors (LV). Even though LV display a more favorable integra-
tion pattern, induction of aberrant splicing [17,18] and insertionalmutagenesis remain a major
concern, as clonal expansion was observed in a gene therapy trial for β-thalassemia [19]. In
addition, two recent independent studies revealed clonal expansion in HIV-1 infected patients
on antiretroviral therapy due to HIV-1 virus triggered insertionalmutagenesis [20,21]. Retrovi-
ral integration is a non-random process which is, depending on the viral genus, associated with
specific chromatin marks and genomic features [22–24]. yRV predominantly integrate in the
vicinity of gene regulatory regions, whereas LV preferably target the body of active transcrip-
tion units [10,25]. Integration is catalyzed by the viral integrase (IN), whereas integration site
choice bias is attributed to the cellular chromatin readers that are co-opted by the viral IN.
Whereas the bromodomain and extra-terminal domain (BET) family of proteins (BRD2, 3 and
4) guideMLV integration [26–28], LV integration is directed by Lens epithelium-derived
growth factor p75 (LEDGF/p75) [29,30]. Both function as molecular tethers in the cell, com-
bining a chromatin-binding and a protein-interacting region (reviewed in [31]). For LEDGF/
p75 (Fig 1A), the chromatin-binding part contains an N-terminal Pro-Trp-Trp-Pro (PWWP)
epigenetic reader domain (aa 1–93), recognizingH3K36me3 chromatin marks [32–36], and a
set of DNA-binding motifs (Fig 1A, [37,38]). Together, these elements allow LEDGF/p75 to
explore the chromatin in a dynamic scan-and-lock fashion [39]. Even though its cellular role is
not fully understood, it is clear that LEDGF/p75 acts as a molecular hub for a variety of endoge-
nous proteins next to the lentiviral integrase (Fig 1A) [40,41],[42],[43],[44]. All these proteins,
including the lentiviral integrase, bind the C-terminal Integrase-Binding Domain (IBD, aa
347–429; Fig 1A) of LEDGF/p75.We and others showed that replacement of the N-terminal
LEDGF/p75DNA-binding region (aa 1–325) with alternative DNA-binding domains retargets
LV integration towards genomic loci bound by these domains [35,45–47]. Fusion of the hetero-
chromatin binding Chromobox protein homolog 1 (CBX1) to the IN-binding C-terminal end
of LEDGF/p75 shifted LV integration into the cognate H3K9mex-marked chromatin environ-
ment, pericentric heterochromatin and intergenic regions [46]. Despite integration in regions
enriched in epigenetic marks associated with gene silencing, transgene expression remained
efficient and resulted in successful phenotypic correction in a cell model for X-CGD [48].
Here we aimed at developing a LEDGF-based tether that results in a more random integra-
tion pattern to reduce the overall risk of insertionalmutagenesis [11,49–51]. First, we truncated
LEDGF/p75 by deleting the N-terminal chromatin-reading PWWP domain that binds
H3K36me3marks directing LEDGF/p75 into the body of active transcription units (Fig 1A
and 1B). In addition, we replaced the PWWP-domain with three alternative viral protein
domains and motifs, described in literature as pan-chromatin recognition peptides since they
bind cellular chromatin without sequence specificity (Fig 1B; Fig 2). Several viruses reside as an
episomal DNA genome in host cells, and evolved strategies to persist during mitosis through
defined chromatin binding motifs. The spumavirus, Prototype Foamy Virus (PFV), contains a
13-amino acid motif in the group-specific antigen (Gag) binding the H2A/H2B core nucleo-
some [52–54]. Likewise, the Kaposi Sarcoma-associatedHerpes Virus (KSHV) genome is teth-
ered to the nucleosomal core via a chromatin binding sequence (CBS) at the N-terminal end of
the latency-associated nuclear antigen protein (LANA) [55]. Finally, in the Beta-Papillomavi-
ruses (PV) a conservedmotif in the E2 hinge promotes binding to chromatin and mitotic chro-
mosomes of the invaded cell [56–58]. Following the generation of stable cells lines, we
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monitored LV integration preferences and evaluated integration sites based on safe harbor
region criteria [59] and determined a genotoxicity profile.
Materials and Methods
Generation of stable cell lines
SIV-based vector transfer plasmids (pGAE) were a kind gift of D. Nègre (Laboratoire de Vec-
torologie Rétrovirale et Thérapie Génique, INSERMU412, IFR 74, Ecole Normale Supérieure
de Lyon, Lyon, France). A lentiviral vector carryingCMV promoter driving a Zeocin resistance
Fig 1. Schematic representation of the LEDGF/p75 domain structure and artificial LEDGF-hybrids. (a)
LEDGF/p75 contains a C-terminal protein-binding domain, coined Integrase Binding Domain (IBD) responsible for
HIV-IN interaction. Several endogenous proteins like Jpo2, PogZ and MLL bind to the same interface. At its N-
terminal end carries multiple chromatin interacting domains, the PWWP domain, the AT hook-like domain (AT) and
three charged regions (CR1, 2, 3). D366 is a pivotal amino acid involved in HIV-IN interaction (arrowhead).
Mutation to Asn (D366N) abolishes HIV-IN interaction. The lower panel (b) depicts the different LEDGF-hybrids,
PFV Gag534-546-ΔN93-LEDGF, HPV5 E2242-257-ΔN93-LEDGF, HPV8 E2240-255-ΔN93-LEDGF and LANA1-31-ΔN93-
LEDGF respectively. Numbers indicate the different amino acid residues. AT, AT-Hook; CR, Charged Region;
SRD, Supercoiled Recognition Domein; IBD, Integrase Binding Domain; PWWP, Pro-Trp-Trp-Pro Domain; PFV,
Prototype foamy virus; LANA, Latency associated nuclear antigen; HPV, Human papilloma virus; LEDGF, Lens
epithelium-derived growth factor; NLS, Nuclear localization signal.
doi:10.1371/journal.pone.0164167.g001
Fig 2. Peptide characteristics. Fig showing the acronyms, aa-sequences and binding characteristics of the peptides used to generate the
artificial LEDGF tethers. PFV, Prototype foamy virus; HPV, Human papilloma virus; KSHV, Kaposi’s sarcoma herpes virus; LANA, Latency
associated nuclear antigen.
doi:10.1371/journal.pone.0164167.g002
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gene and a LEDGF specificmiRNA-based shRNA was described earlier [60] and used to gener-
ate stable LEDGFKD cells. All LEDGF/p75 hybrid expression constructs were cloned into the
pGAE backbone and cloning steps sequence verified.
➢ Cloning of ΔN93-LEDGF and ΔN93-LEDGFD366N controls for the LEDGFΔN93-LEDGF
fusions
pGAE_SFFV_ZnF4_ ΔN93_BC_I_BsdR_WPREcl.9 and pGAE_SFFV_ZnF4_ ΔN93
BC_D366N_I_BsdR_WPREcl.3 were digested using BglII& XhoI. Ligation of the synthetic
adaptor Ad_BglIIKO_AgeI_kozak generated pGAE_SFFV_ ΔN93_BC_I_BsdR_WPREcl. E
and pGAE_SFFV_ ΔN93_BC_D366N_I_BsdR_WPREcl. 5. We further refer to the controls as
ΔN93-LEDGF and ΔN93–LEDGFD366N respectively.
➢ Cloning of LEDGFΔN93-LEDGF and ΔN93-LEDGFD366N hybrids
pGAE_SFFV_ZnF4_ ΔN93_BC_I_BsdR_WPREcl.9 and pGAE_SFFV_ZnF4_ ΔN93
BC_D366N_I_BsdR_WPREcl.3 were digested using BglII& XhoI. Ligation of the synthetic




• pGAE_SFFV_ PFVCBS13_ ΔN93_BC_I_BsdR_WPREcl.13
• pGAE_SFFV_ PFVCBS13_ ΔN93_BC_I_BsdR_WPREcl.4
• pGAE_SFFV_HPV5E2_16 _ ΔN93_BC_I_BsdR_WPREcl.19
• pGAE_SFFV_HPV5E2_16 _ ΔN93_BC_I_BsdR_WPREcl.8
• pGAE_SFFV_HPV8E2_16 _ ΔN93_BC_I_BsdR_WPREcl.23
• pGAE_SFFV_HPV8E2_16 _ ΔN93_BC_I_BsdR_WPREcl.11
All cloning steps were confirmed by restriction digest and sequencing.
Cell culture
All cells were grown in a humidified atmosphere containing 5% CO2 at 37°C. HeLaP4
310 LEDGF/p75 depleted cells ([46], further referred to as LEDGFKD cells) were grown in
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO-BRL,Merelbeke, Belgium) supple-
mented with 5% v/v heat inactivated fetal calf serum (FCS; Sigma-Aldrich, Bornem, Bel-
gium), 0.005% w/v gentamicin (GIBCO), 0.05% w/v geneticin (GIBCO) and 0.01% w/v
zeocin (Life Technologies, Ghent, Belgium). These cells are monoclonal LEDGFKD cells,
derived from HeLaP4 cells (gift from P. Charneau, Institut Pasteur, Paris, France). HelaP4
cells were grown on DMEM (GIBCO) supplemented with 5% v/v heat inactivated fetal calf
serum (FCS; Sigma-Aldrich), 0.005% w/v gentamicin (GIBCO)& 0.05% w/v geneticin
(GIBCO).HEK 293T cells (gift from O. Danos, Evry, France) were cultured in DMEM
medium (GIBCO)with 8% v/v heat inactivated FCS (Sigma-Aldrich) and 0.005% w/v gen-
tamicin (GIBCO). SupT1 cells were cultured in Roswell Park Memorial Institutes medium
(RPMI, GIBCO-BRL,Merelbeke, Belgium) supplemented with 10% v/v heat inactivated
fetal calf serum FCS (Sigma-Aldrich, Bornem,Belgium)and 0.005% w/v gentamicin
(GIBCO).Nalm pre-B cells were cultured in RPMI (GIBCO)with 10% v/v heat inactivated
FCS (Sigma-Aldrich) and 0.005% w/v gentamicin (GIBCO).
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Retroviral vector production (SIV-based) and transduction
Lentiviral vector production was performed as described earlier [61]. Briefly, for the generation
of vesicular stomatitis virus glycoprotein (VSV-G) pseudo-typedSIV-based lentiviral vectors,
HEK 293T cells were transfected with the packaging plasmid specific for SIV (pAd_SIV3+; gift
from D. Nègre, Lyon, France), the envelope plasmid encodingVSV-G (pLP-VSVG #646 B,
from Invitrogen) and respective transfer plasmids, using polyethylenimine (PEI; Polysciences,
Amsterdam, The Netherlands). After collecting the supernatant, the mediumwas filtered using
a 0.45 μm filter (Corning Inc., Seneffe, Belgium) and concentrated using a Vivaspin 15 50,000
MW column (Vivascience, Bornem, Belgium). The vector containing concentrate was then ali-
quoted per 50 μl and stored at -80°C. Stable cell lines expressing a LEDGF hybrid were gener-
ated by transduction of polyclonal LEDGF/p75KD cells with SIV-based vectors and subsequent
selectionwith 0,0003% w/v blasticidin (Invitrogen). For lentiviral transduction experiments
(LV eGFP T2A fLuc) cells were transducedON. 72 hours post-transduction cells were har-
vested when 90% confluent and used for eGFP FACS-analysis or luciferase activity. The
remainder of the transduced cells was further cultivated for at least 20 days to eliminate non-
integrated DNA and submitted for integration site sequencing.
Immunocytochemistry and Laser scanning microscopy
Cells were transfected using Lipofectamine 2000 (Life Technologies, Merelbeke, Belgium) as
described earlier [62]. LEDGF-hybrids were detectedwith the primary polyclonal rabbit anti-
LEDGF480-530 antibody (A300-848a; 1/500; Bethyl Laboratories-Imtec Diagnostics N.V., Ant-
werpen, Belgium) and secondary polyclonal goat anti-rabbit antibody (1/500 in PBS, goat-
αRb488; Bethyl Laboratories-Imtec Diagnostics N.V., Antwerpen, Belgium). Confocal images
were acquired using an LSM 510 META imaging unit (Carl Zeiss, Zaventem, Belgium). Alexa-
488 was excited at 488 nm (AI laser), mRFP at 543 (HeNe laser) and DAPI at 790 nm (Spectra-
physics Mai Tai laser; Spectra Physics, Mountain View CA). After the main beam splitter (HFT
KP 700/543 for mRFP, HFT UV/488/543/633 for eGFP, and HFT KP650 for DAPI) a second-
ary dichroic beam splitter was used to divide the fluorescence signal (NFT 490 for eGFP, NFT
545 for mRFP). Distinct signals were directed to different detectors and data analysis was per-
formed with the LSM image browser. Overlay images were obtained using ImageJ freeware.
Western Blot
Protein concentration of 1% SDS (AppliChem, Leuven, Belgium) protein extracts sheared with
a 27 G needle (Terumo, Leuven, Belgium)was determined using a bicinchoninic acid (BCA)
protein assay (Pierce, Aalst, Belgium). Proteins were separated on a 12.5% w/v SDS-polyacryl-
amide gel and transferred to a polyvinylidene difluoridemembrane (PVDF; BioRad) using an
XCell SureLock electrophoresis system (Invitrogen). LEDGF-hybrids were detected using 1/
2.000 polyclonal rabbit anti-LEDGF480–530 antibody (A300-848a; Bethyl Laboratories-Imtec
Diagnostics N.V., Antwerpen, Belgium) and 1/5 000 secondary antibody (polyclonal goat anti-
rabbit antibody coupled with horse radish peroxidase (HRP); Dako). Chemiluminescence was
measured using a ECL plus western blotting detection kit (Amersham Biosciences, Roosendaal,
The Netherlands). Equal loading was verifiedwith a primarymonoclonal antibody directed to
α-tubulin (mouse, 1/10 000, 1 h at room temperature; T5168, Sigma-Aldrich) and secondary
antibody in blocking buffer (1/10 000, polyclonal goat-anti mouse labelled with HRP; Dako).
Visualization was done by chemiluminescence (Pierce ECLWestern Blotting Substrate,
Thermo scientific).
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Luciferase assay
Cells were transducedwith LV eGFP T2A fLuc and lysed with 70 μl of lysis buffer (50 mmol/l
Tris pH 7.5, 200 mmol/l NaCl, 0.2% NP40, 10% glycerol). FLuc activity was determined using
the ONE-glo luciferase assay system according to the manufacturers protocol (Promega, Lei-
den, The Netherlands) and normalized to the total protein concentration in order to correct
for differences in metabolic state. The total protein concentration was measured in parallel
using a bicinchoninic acid (BCA) protein assay (Pierce, Aalst, Belgium).
Flow cytometric analysis
Cells were transducedwith LV eGFP T2A fLuc and harvested when 95% confluent. eGFP/YFP
fluorescencewas monitored by Flow cytometric analysis (FACS, Fluorescence activated cell
sorting) using a FACSCalibur flow cytometer (BD Biosciences, Erembodegem,Belgium).Data
analysis was performedwith the CellQuest Pro software (BD Biosciences, Erembodegem-Aalst,
Belgium). The percentage of eGFP positive cells (% of gated cells) multiplied by the mean fluo-
rescence intensity (MFI) is further referred to as overall transduction efficiency.
Integration site amplification and sequencing
Transduced HeLaP4 cells were further cultivated for at least 20 days to eliminate non-inte-
grated DNA. Cells were harvested when ca. 90% confluent. Genomic DNA was extracted
using the GenElute Mammalian Genomic DNA miniprep kit (Sigma-Aldrich). Integration
sites were amplified by linker-mediated PCR as described previously [30]. Genomic DNA
was digested usingMseI and linkers were ligated (S1 Fig). Proviral-host junctions were
amplified by nested PCR using Barcoded primers, generating 454 libraries. This enabled
pooling of PCR products into one sequencing reaction. Products were gel-purified and
sequenced using 454/Roche pyrosequencing (Titanium technology, Roche) on the 454
GS-FLX-instrument at the University of Pennsylvania. Reads were filtered based on perfect
match to the LTR linker, Barcode and flanking LTR. All sites were mapped to the human
genome requiring a perfect match within 3bp of the LTR end. Three random control sites
were computationally generated and matched with respect to the distance to the nearestMseI
Cleavage site for each experimental site (matched random control, MRC). A more detailed
explanation can be found in the supplementary guidelines of [63]. Normalization of experi-
mental HIV-derived lentiviral vector sites to those of the MRC sites functions as a control for
recovery bias due to cleavage by restriction enzymes. Analysis was performed as described
previously and genomic heat maps generated using the INSIPID software (Bushman Lab,
University of Pennsylvania). [30]. A detailed guide to interpret the heat maps presented can
be found in [63]. The computation of DNase I site density was based on a table of DNase I
sites obtained from [64]. Datasets used in the safe harbor analysis were retrieved from
ENSEMBLE and/or UCSC (TxDB knownGenes, miRNA biotype, UCR; hg19) using Bio-
MART [65]. The Allonco-list was used for oncogenes as published in [66]
Results
Generation of LEDGF-hybrids and stable cell lines
In an effort to distribute lentiviral vector integrationmore randomly over the genome, wemodified
LEDGF/p75, the cellular tether of the HIV Pre-Integration complex (PIC), by deleting the chroma-
tin-reading PWWP-domain (ΔN93-LEDGF, Fig 1A and 1B) [32–34] relying on the remaining
non-specificDNA-interacting regions in LEDGF93-325, such as the AT-hook domains and the
CRs (Fig 1A; [39]). In addition, we generated LEDGF-hybrids where the PWWP-domain was
Safer, Random Lentiviral Vector Integration
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exchanged with a set of alternative pan-chromatin recognitionpeptides of viral origin (Fig 1B, and
Fig 2). Prototype Foamy Virus chromatin binding segment of Gag534-546 (PFVGag534-546) [52–54],
Human Papilloma Virus serotype 5 E2242-257, Human Papilloma Virus serotype 8 E2240-255 (HPV5
E2242-257 and HPV8 E2240-255, respectively)[56–58] and Kaposi’s Sarcoma Herpes Virus Latency
AssociatedNuclear Antigen1-31 (KSHV LANA1-31) [55] were used to replace the PWWP domain,
generatingΔN93-LEDGF, PFVGag534-546-ΔN93-LEDGF, HPV5 E2242-257-ΔN93-LEDGF, HPV8
E2240-255-ΔN93-LEDGFand KSHV LANA1-31-ΔN93-LEDGF fusions, respectively. All above-men-
tioned LEDGF-hybrids were used to complement LEDGF/p75-depletedcells (HeLaP4 (LEDGFKD)
[60] and Nalm (LEDGFKO) cells [67]) employing SIV-based lentiviral vectors. As a positive control,
cells were complemented withWT LEDGF/p75 (referred to as LEDGF/p75back complementation
(LEDGFBC)). In order to control for non-specific effects resulting from the expression of the fusion
proteins we also generated stable cell lines expressing the respective chimeras carrying a D366N
mutation in the LEDGF/p75part, which abrogates the interactionwith lentiviral integrase (IN)
[68]. Protein integrity was corroborated by western blot analysis, with all LEDGF-hybridsmigrat-
ing at the predictedmolecularweights (S2 Fig). Of note, protein levels of PFVGag534-546-ΔN93-
LEDGFwere lower in all experiments.Viability and growth rates of all cell lines were comparable
to the parental HeLaP4 cells (data not shown).
LEDGF-hybrids locate to the nucleus and display a distinct subnuclear
distribution
In a first step, we evaluated the subcellular localization of the truncatedΔN93-LEDGF and the
respectiveΔN93-LEDGF-hybrids by immunocytochemistry (Fig 3). Complementation of
LEDGF-depletedHeLaP4 cells (LEDGFKD) with LEDGFBC resulted in a typical pattern of
dense, fine speckles in the nucleoplasm excluded from the nucleoli during interphase (Fig 3C),
phenocopying the endogenous LEDGF/p75 pattern (Fig 3A), which is in line with earlier
reports [46]. Contrary, LEDGF/p75 lacking the chromatin-reading PWWP-domain exhibited
a more diffuse nuclear distribution and located to the nucleoli as well (ΔN93-LEDGF, Fig 3D).
In addition, all ΔN93-LEDGF peptide-fusions located to the nucleus (Fig 3E–3H), displaying a
unique sub-nuclear distribution: the PFV Gag534-546- and the KSHV LANA1-31-fusion to
ΔN93-LEDGF showed a punctate appearance in the nucleus and were excluded from nucleoli
(Fig 3E and 3H), contrary to both HPV5 E2242-257- and HPV8 E2240-255-ΔN93-LEDGF fusions
that were enriched in the nucleoli (Fig 3F and 3G). Similar subcellular distributions were
observed for the respective cognate LEDGFD366N-hybrids (data not shown).
LEDGF-peptide fusions rescue lentiviral vector transduction
Next, we assessedwhether the ΔN93-LEDGF-hybrids supported lentiviral vector transduction by
complementing LEDGF-depleted cells (LEDGFKD) and employing wild-typeLEDGF/p75 comple-
mented cells (LEDGFBC) as control. The respectiveHeLaP4 cell lines were challengedwith a dilu-
tion series of a lentiviral vector (multiplicity of infection (MOI) = 1, 0.2 or 0.04 (indicated in lighter
colors)) encoding enhanced green fluorescent protein (eGFP) and firefly luciferase (fLuc) reporters
[61]. Transduction efficiencieswere determinedby flow cytometrymonitoring eGFP fluorescence
(Fig 4A and 4B, showing transduction efficiency(eGFP positive cells; %Gated) andMean Fluores-
cence Intensity (MFI), respectively). Complementation of LEDGF-depleted cells with LEDGFBC
restored transduction efficiency(Fig 4A) (, p<0.005; two-tailed t-test relative to LEDGFKD), in
line with earlier reports [46,69]. Complementation of LEDGFKD cells with ΔN93-LEDGF, lacking
the chromatin interacting PWWP-domain, partially rescued lentiviral transduction (78% com-
pared to LEDGFBC) (Fig 4A, , p<0.005 compared to KD, two-tailed t-test). Addition of chroma-
tin binding peptides to replace the PWWP domain displayed a significantly improved transduction
Safer, Random Lentiviral Vector Integration
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relative toΔN93-LEDGF (, p<0.005; two-tailed t-test), reaching efficienciescomparable to
LEDGFBC (Fig 4A). Similar results were obtained for different vector dilutions (Fig 4A) or when
assessing complemented LEDGF/p75knock-out cells (Nalm-/-, data not shown) [67] or when eval-
uating fLuc as a reporter (data not shown). Looking at Mean Fluorescence intensities all LEDGF-
peptide fusions were about 20% lower than LEDGFBC (Fig 4B). In addition to transduction efficien-
cies, we also determined the number of integrated copies (Fig 4C). Reintroductionof LEDGF/p75
(LEDGFBC) significantly improved vector integration (±-3.5-fold compared to LEDGFKD (,
p<0.005, two-tailed t-test).
Likewise,ΔN93-LEDGF and all LEDGF-peptide fusions restored vector integration (2.5-fold
more compared to LEDGFKD, , p<0.005, two-tailed t-test), albeit still to a lesser extent
(reaching 68–74% of LEDGFBC, Fig 4B). The increased transduction efficiencies (%Gated)
closely correlate with an increase in integrated viral vector copies (Fig 4C). Complementation
with ΔN93-LEDGF alone, lacking any additional chromatin-tether, resulted in lower integrated
copy numbers than ΔN93-LEDGF fused to chromatin engaging peptides (p-values<0.005, two-
tailed t-test relative to ΔN93-LEDGF; 66.7% of LEDGFBC), supporting the notion that the chro-
matin-reading PWWP domain of LEDGF/p75 is not an absolute requirement for efficient
integration.
LEDGF-peptide fusions efficiently redistribute lentiviral integration
After showing that complementation of LEDGF/p75-depletedcells with ΔN93-LEDGF or any
of the LEDGF-hybrids rescued vector integration, we determined the integration profiles in the
respective cell lines. HIV-based viral vector integration sites were amplified and sequenced as
described earlier [30,46], yielding a total of 62670 unique integration sites and their computa-
tionally generated matched random control (MRC) sites. Note that SIV-based viral vectors
were used to complement LEDGF/p75-depleted cells, in order to avoid interference with the
HIV-based viral vector integration site amplification and analysis. First, we analysed integra-
tion relative to a set of defined genomic features (Fig 5, Fig 6). Lentiviral vector integration in
wild-typeHeLaP4 cells (endogenous LEDGF/p75, Fig 6) is traditionally enriched in the body
of transcription units (75.0% in RefSeq genes; Fig 5) but disfavoured transcription start sites
(TSS) and promoter regions (2.0% within 2kb of the 5’ of a RefSeq gene and 3.1% within 2kb of
a CpG island) [10,25]. LEDGF-depletion results in a more random integration site distribution,
characterized by reduced integration into genes (51.0% in RefSeq genes) and increased integra-
tion close to TSS (5.4%) and CpG islands (7.0%), in line with previous work [30,46,70]. This
phenotype was fully reverted upon LEDGF/p75 complementation (LEDGFBC; 75.6% in RefSeq
genes). Comparable data were obtained for larger window sizes (only 2kb and 4kb are shown
in Fig 5). Integration site distributions in cells expressing the respective LEDGFD366N mutants
were not different from LEDGFKD cells (n = 16473; data not shown). Interestingly, the mere
ablation of the PWWP domain (ΔN93-LEDGF) resulted in an overall more random distribu-
tion compared to LEDGFKD cells, with decreased integration near retrovirus-specific features
like gene bodies, TSS and promoter regions ( p<0.001; χ2 test compared to LEDGFKD; Fig
5). Complementation of LEDGF-depleted cells with LEDGF-peptide fusions resulted in a com-
parable more randomized distribution ( p<0.001; χ2 test compared to LEDGFKD; Fig 5). In
Fig 3. Subcellular localization of LEDGF/p75-hybrids in interphase cells. LEDGF/p75 depleted cell
lines were complemented with the respective LEDGF-fusions. Laser scanning confocal images of HelaP4
cells, stained using an Ab recognizing LEDGF480-530, are shown in green. Nuclei were stained using Dapi
(shown in blue). A merge of green and blue fluorescence is shown. Data depicted are representative for the
respective cell lines. PFV, Prototype foamy virus; LANA, Latency associated nuclear antigen; HPV, Human
papilloma virus; LEDGF, Lens epithelium-derived growth factor; DAPI, 4’,6-Diamidino-2-Phenylindole.
doi:10.1371/journal.pone.0164167.g003
Safer, Random Lentiviral Vector Integration
PLOS ONE | DOI:10.1371/journal.pone.0164167 October 27, 2016 9 / 23
Safer, Random Lentiviral Vector Integration
PLOS ONE | DOI:10.1371/journal.pone.0164167 October 27, 2016 10 / 23
a more elaborate analysis, we analysed global integration preferences and included a wide selec-
tion of genomic features, depicted as a genomic heatmap (Fig 6), comparing integration site
data sets obtained fromHeLaP4 LEDGFKD cells to those of cells complemented with the
respective LEDGF-hybrids. Tile color depicts the correlation for an integration dataset with the
respective genomic feature (left) relative to matched random controls, as indicated by the col-
ored receiver operating characteristic (ROC) curve area scale at the bottom of the panel.
LEDGF/p75 depletion shifts integration out of transcriptionally active regions wich is reverted
upon complementation with LEDGF/p75 (compare LEDGFKD and LEDGFBC; shown in Fig 6),
in line with previous data [30,46,70]. Cells complemented with ΔN93-LEDGFdisplayed an
more randomly distributed integration profile, with tiles overall coloring less red or blue com-
pared to LEDGFKD, integrating less near DNase sensitive regions, CpG-islands and GC-rich
regions compared to LEDGFKD ( p<0.001, Wald statistics). Introduction of the heterolo-
gous HPV E2 and LANA1-31-peptide fragments to replace the PWWP-domain resulted in a
ΔN93-LEDGF-like integration profile when compared to LEDGFKD (p<0.001), whereas inte-
gration for PFV Gag534-546-ΔN93-LEDGFwas less random.When displaying statistics relative
to ΔN93-LEDGF (S3A Fig) integration frequencies near these genomic features is not signifi-
cantly different betweenΔN93-LEDGF and the respectiveΔN93-LEDGFpeptide-fusions, except
for PFV Gag534-546-ΔN93-LEDGF (Fig 6). The reproducibility of the data observed for HPV5
E2242-257-ΔN93-LEDGF and HPV8 E2240-255-ΔN93-LEDGF complemented cell lines and the
pronounced redistribution towards more random relative to LEDGFBC (S3B Fig) underscores
the effectiveness of LEDGF-based artificial tethers for retargeting of LV integration. Next to
Fig 4. Rescue of lentiviral vector transduction by artificial LEDGF-hybrids. LEDGF-fusions were evaluated for their ability to
support lentiviral vector transduction. LEDGF-depleted HelaP4-based cell lines stably complemented with LEDGF-hybrids were
challenged with a VSV-G pseudo-typed lentiviral reporter vector encoding enhanced Green Fluorescent Protein (eGFP). Fluorescence
was measured by fluorescence activated cell sorting and the different variables plotted:. (a) Percentage eGFP positive cells (transduction
efficiency) and (b) Mean Fluorescence Intensity (MFI). Data are compiled for a representative experiment and depict averages of 3
replicates for 3 different vector dilutions (mean ± SD). (c) Lentiviral integrated proviral copies were determined by Q-PCR analysis on
genomic DNA extracts of cells transduced with an MOI = 1. Data are represent the mean of 3 replicates ± SD. Statistical significance is
calculated using a two-tailed t-test relative to LEDGFKD or ΔN93-LEDGF. PFV, Prototype foamy virus; LANA, Latency associated nuclear
antigen; HPV, Human papilloma virus; LEDGF, Lens epithelium-derived growth factor.
doi:10.1371/journal.pone.0164167.g004
Fig 5. Integration frequency near genomic features. Fig showing the percentage HIV-derived lentiviral vector integration sites relative
to features specific for integration viral vectors such as integration into the body of genes (Refseq genes, InRefGene), integration within
2kb-4kb windows near Transcription Start Sites (X5-end of genes, TSS), midpoint of CpG islands or DNase I-hypersensitive sites (DHS),
counted in both the 5’ and 3’ direction. Dataset details are described in the MM section. Asterisks depict a significant deviation from LEDGF
KD (two-tailed Chi-square test; ***, p-values <0.001). TSS, Transcription start sites; DHS, DNase I-hypersensitive sites; PFV, Prototype
foamy virus; HPV, Human papilloma virus; KSHV, Kaposi’s sarcoma herpes virus; LANA, Latency associated nuclear antigen; MRC,
matched random control.
doi:10.1371/journal.pone.0164167.g005
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integration relative to genomic features, we also analyzed integration site densities near epige-
netic features (Fig 6B). The epigenetic heat map displays yellow and blue tiles, with blue tiles
indicating that integration frequency is enriched near these marks relative to MRC, whereas
yellow tiles indicate that integration is disfavored compared to MRC. A near random distribu-
tion would result in a black tile. As reported previously, lentiviral integration correlates with
histone marks associated with open and transcriptionally active chromatin (H3K4 mono-, di-
and tri methylation, H3K14 and H4 acetylation, as well as acetylation and monomethylation of
H3K9/K27/K79,H4K20 and H2BK5, . . .): [8] while disfavoring integration in transcriptionally
silent regions or heterochromatin (H3K27me3, H3K9me3 or H4K20me3 and H3K79, respec-
tively): [8] (WT; Fig 6). Depletion of LEDGF/p75 (LEDGFKD) resulted in a more random dis-
tribution (with tiles displaying a less pronounced blue or yellow color, and shifting towards
black). This tendency was more outspoken for ΔN93-LEDGF and the HPV E2 and LANA1-31-
peptide fusions compared to LEDGFKD (Fig 6B), ΔN93-LEDGF (S4A Fig) or LEDGFBC (S4B
Fig), potentially because integration in LEDGF-depleted cells, at least in part, is tethered by
HRP-2 [67].
Artificial peptide-LEDGF/p75 hybrids result in a safer integration profile
Together, the presented above data indicate that lentiviral vector integration preferences are
defined by LEDGF/p75 as a cellular tether, and are mostly dictated by the N-terminal PWWP-
domain. The mere deletion of this domain, or replacement with alternative chromatin-interact-
ing modules redistributes vector integration sites in a more random fashion. The question
remains whether redistribution of proviral integration sites obtained for our LEDGF-hybrids
also translated in a safer therapy, with a lower chance on insertionalmutagenesis. In an effort
to get a better view on the safety profile, we calculated integration frequencies near a specific
set of previously defined criteria [59,66], such as transcription start sites (<50kb), oncogenes
(<300kb) or miRNA coding regions (<300kb), transcription units and ultraconservedele-
ments to define potentially unsafe integration events. The large window sizes impose a very
stringent selection for lentiviral integration events away from these features, which in turn can
thus be considered as more safe [59]. For each data set we evaluated the percentage of unsafe
integrations (Fig 7 and S5 Fig) and in addition determined the percentage of safe sites (events
not captured in any of the other criteria; Fig 7, % safe). When calculating the percentage in the
parental cell line only 5.4% of all LV integration sites may be considered safe. LEDGF/
p75-depletion results in a shift to 16.3% safe sites (p-value<0.005, Pearsons Chi-square com-
pared to the LEDGFWT control condition), a phenotype that was fully reverted upon LEDGF/
Fig 6. LEDGF-hybrids retarget lentiviral integration towards a more randomized pattern. (a) Genomic heat map comparing
integration site data sets obtained from HeLaP4 LEDGF/p75 KD cells overexpressing different artificial LEDGF-hybrids to
genomic features. Tile color depicts the correlation for an integration dataset with the respective genomic feature (left) relative to
matched random controls, as indicated by the colored receiver operating characteristic (ROC) curve area scale at the bottom of
the panel. Statistical significance (asterisks, ***p<0.001 ranked Wald tests) is shown relative to LEDGF KD population (double
dash). Columns indicate different data sets, while rows indicate different genomic features analyzed (described in [63]). LANA,
Latency associated nuclear antigen; HPV, Human papilloma virus; PFV, Prototype foamy virus; a; LEDGF, Lens epithelium-
derived growth factor. (b) Epigenetic heat map comparing integration site data sets obtained from HeLaP4 LEDGF/p75 KD cells
overexpressing different artificial LEDGF-hybrids to epigenetic features. Tile color depicting a positive or negative correlation to
the respective epigenetic feature (10kb windows), relative to MRC, as indicated by the receiver operating characteristic (ROC)
curve area scale at the bottom of the panel. Statistical significance (asterisks, ***p<0.001, ranked Wald tests) is shown relative to
LEDGF KD population (dashed). Columns indicate different data sets while rows indicate different epigenetic features analyzed.
Included features were limited to those identified in high-throughput studies HeLaP4 and primary CD4+ T-cells. Detailed
information on epigenetic marks and their roles can be found in [87,88]. LANA, Latency associated nuclear antigen; HPV, Human
papilloma virus; PFV, Prototype foamy virus; a; LEDGF, Lens epithelium-derived growth factor.
doi:10.1371/journal.pone.0164167.g006
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p75BC complementation (5.4%, no significant difference compare to LEDGFWT). Ablation of
the N-terminal PWWP-domain again boosted the percentage safe integration events to 19.7%
(p-value<0.005, Pearsons Chi-square compared to the LEDGFWT control condition). Addi-
tion of heterologous peptide fragments KSHV LANA1-31 and HPV8 E2240-255 to the N-termi-
nal end of LEDGF93-530 slightly increased the % safe integrations relative to ΔN93-LEDGF
(S5A Fig) with complementation up to 20.2% for HPV5 E2242-257-ΔN93-LEDGF, 21.2% for
HPV8 E2240-255-ΔN93-LEDGF and 21.6% for KSHV LANA1-31-ΔN93-LEDGFwhen consider-
ing these criteria (p-value<0.05, Pearsons Chi-square compared to the ΔN93-LEDGF control
condition). Relative to the LEDGFBC condition our LEDGF-chimera increased the percentage
of safe sites more than 3 fold (p-value<0.005, Pearsons Chi-square, S5B Fig). Of note, for the
MRC conditions, we obtained a maximum of 30% integrations in safe harbors.
Discussion
Integration of retroviral vectors into the host cell genomemakes them invaluable tools for gene
therapeutic applications where life-long correction is key. Previous reports showed effective
gene transfer enabling long-term gene correction (For a review see [71]). However, severe
adverse events in these clinical studies (using full-LTR driven gamma-retrovirus vectors) raised
serious concerns regarding the safety of gene therapy when using integrating vectors (derived
from the family of retroviruses) [14,15]. The yRV preference for integration into enhancer
regions and concomitant activation of proto-oncogenes led to malignant transformation of
cells and clonal expansion [10–12]. Therefore, multiple studies have been triggered to increase
the safety of the used retroviral vectors, which include the use of other subtypes (lenti or alpha
instead of gammaretroviral), SIN-LTR design [72–75], tissue specific promoters [76], changing
integration properties [45–47] and insulator sequences as enhancer and silencer blockers [77].
Meanwhile, lentivirus vectors became the mean of choice when using retroviruses for gene
transfer and clinical gene therapy due to their safer integration profile and lower genotoxicity
in preclinical models. As such, any successfulmodification avoiding an increased integration
of these vectors into gene coding regions may be relevant for translation into the clinics. Stable
integration however will always imply the intrinsic risk of vector-induced genomic
Fig 7. Integration frequency near safe harbor criteria. Fig showing the percentage HIV-derived lentiviral vector integration frequencies
near features (TSS, Oncogenes [66], miRNA encoding regions, Transcription units and ultra conserved regions) that, when hit, are
considered to be UNsafe as defined in [59] (Dataset details are described in the MM section). As such these features are used to define safe
harbors as regions that fall outside these criteria. Percentages depict the fraction of integrations falling within the corresponding range
relative to the criteria. The % of integrations negatively associated with these 5 features is used to calculate a safety profile. (*, p-value <0.5;
**, p-value <0.05;***, p-value <0.005, Pearsons Chi-square compared to LEDGFWT control). TSS, Transcription start sites; UCR, Ultra
conserved regions; PFV, Prototype foamy virus; HPV, Human papilloma virus; KSHV, Kaposi’s sarcoma herpes virus; LANA, Latency
associated nuclear antigen; MRC, matched random control.
doi:10.1371/journal.pone.0164167.g007
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perturbation, open reading frame-disruption, leading to loss of function or transcriptional
deregulation of neighbouring genes as indicated by the report on SIN-LV affected splicing [78].
In addition, also LV integration may lead to clonal dominance as reported in the beta-thalasse-
mia trial, which could be an indicator of upcomingmalignant transformation [19]. Therefore it
is important to gain additional mechanistic insights into the molecularmechanism of integra-
tion and integration site selection for LVs to be accepted for general therapeutic use. We and
others substantially contributed to the elucidation of the role of LEDGF/p75 as a molecular
tether of lentiviral vector integration. As a cellular cofactor of lentiviral integration, LEDGF/
p75 orchestrates lentiviral integration preference by binding H3K36me3 in the body of active
transcription units via its N-terminal PWWP domain, but it is the vector-encoded integrase
that catalyzes the integration reaction. Depletion of LEDGF/p75 by knockdown or knockout
strategies shifts lentiviral vector integration out of active genes, yet integration is not
completely random [67,79], which at least in part can be explained by residual targeting via
HRP-2 [67]. Here we set out to study whether different LEDGF-hybrids could be generated to
distribute lentiviral integration sites more randomly. This line of vector development is based
on the further increasing interest in new vector platforms displaying a close-to-random inser-
tional profile potentially reducing the probability of proto-oncogene activation lowering the
genotoxic potential [51,80,81]. In an effort to achieve a more random integration site distribu-
tion, we deleted the specific chromatin-binding PWWPmodule of LEDGF/p75 (aa 1–93), or
we replaced it with alternative pan-chromatin binding modules. In case of LEDGF/p75, it is
demonstrated that the PWWP domain recognizesH3K36me3, a chromatin mark that is partic-
ularly enriched in the body of active transcription units [32–36]. Complementation of LEDGF-
depleted cells with a LEDGF/p75-protein that had its PWWP domain deleted (ΔN93-LEDGF)
or replaced with alternative chromatin binding modules showed unique subnuclear distribu-
tions for each of the constructs, indicating that these deletion of the PWWP domain, or the
replacements with any of the other peptides, resulted in a specific redistributionwithin the
nuclear compartment of the artificial LEDGF chimera (Fig 3). The latter phenotype can be
attributed to the AT-hook motifs and charged regions present in the N-terminal end of ΔN93-
LEDGF, together with the specific peptides that replaced the PWWP domain. After working
up integration sites, analysis showed that lentiviral integration preferences for most of the con-
structs resulted in a more random distribution than under LEDGF depleted conditions (geno-
mic and the epigenetic heat map representations; Fig 6A and 6B), except for PFV Gag534-546-
ΔN93-LEDGF. For example, in the latter cells LV integration was still enriched near epigenetic
markers for transcriptionally active chromatin, albeit less outspoken than observedwith
LEDGFWT and LEDGFBC cells (S4B Fig). Interestingly, peptide addition was not required to
obtain a more random distribution. Lentiviral integrations in ΔN93-LEDGF expressing cells
were redistributed in a fairly randommanner, with tile colors shifting to grey and black (for
the genomic and the epigenetic heat map representations, respectively) indicating that integra-
tion frequencies for these features are not enriched nor depleted compared to the matched ran-
dom integration site distribution. Comparison with LEDGFKD shows that integration is more
randomly distributed than under LEDGFdepletion ( p<0.001,Wald statistics; Fig 6A and
6B). Fusion of short pan-chromatin binding peptides to the truncatedΔN93-LEDGF resulted in
similar shifts towards a more randomized integration profile. The fact that all peptide fusions
display a unique subnuclear location, suggest that their interaction with chromatin is different.
Even though the overall integration frequencies are highly similar (considering the genomic
and the epigenetic features analyzed), larger integration site datasets (>10e5 sites) would be
required to allowmore detailed analysis on the specific subsets. In an effort to estimate the
effect of the more randomized distribution on safety, we calculated the frequency of integration
relative to a set of safe harbor criteria for the individual integration site datasets [59]. This
Safer, Random Lentiviral Vector Integration
PLOS ONE | DOI:10.1371/journal.pone.0164167 October 27, 2016 15 / 23
analysis showed that the more random distributions resulted in a lower genotoxic profile with
18–22% of integrations meeting safe harbor criteria for our LEDGF-chimera compared to only
5.4% for cells carryingwild-type LEDGF/p75, all LEDGF-chimera resulted in a safer distribu-
tions over the genome. Fully targeted integration towards safe harbor regions like the AAVS1
or CCR5 locus would be the ultimate solution to circumvent insertionalmutagenesis
[59,66,82]. Severalmethods for site-directed gene correction have been developed using genetic
scissors based on Zinc-finger nucleases, transcription activator like effector nucleases or more
recently RNA-guided nucleases (CRISPR/Cas9) (for a review [83]). However, site directed inte-
gration would no doubt impair transduction efficiencies.Our approach improves the therapeu-
tic potential of lentiviral vectors by decreasing the risk/benefit ratio, still supporting high
transduction efficiencies.The fact that integration can be directed to genomic regions that are
not targeted under wild-type conditions nor LEDGF-depleted conditions, indicates that inte-
gration in these areas is disfavored due to the absence of a tether, rather than the presence of
specific obstacles such as steric hindrance resulting from the condensed chromatin structure.
As an alternative to the generation of stable cell lines as employed here, we demonstrated ear-
lier that mRNA-electroporation ensures timely, high-level recombinant protein expression
that is sufficient to retarget lentiviral vector integration [48]. When combined with IN mutant
lentiviral vectors that selectively bind complementary LEDGF/p75 variants [84], this approach
should be broadly applicable to introduce therapeutic or suicide genes for cell therapy, such as
genetic modification of patient-specific iPS cells and improve safety of lentiviral vectors. With
the occurrenceof potential adverse effects being of multi-factorial nature [85] novel therapeutic
approaches should be evaluated in relevant functional assays able to predictively assess the
cytotoxicity observed in vivo [86], a continuous effort aiming at abolishing the risk of inser-
tional mutagenesis will be required for gene therapy to become a broadly accepted treatment
alternative.
Supporting Information
S1 Fig. Oligo sequences used in this study. Fig depicting the different oligos used in this study
together with their nucleotide sequence.
(EPS)
S2 Fig. Western analysis of LEDGF-fusions.LEDGFdepleted cell lines were complemented
with the respective LEDGF-hybrids. Total cell lysates were prepared and separated on a 12,5%
SDS gel. An antibody recognizing LEDGF325-530 was used for detection. β-tubuline detection
was used as an equal loading control. WT, Wild type; KD, Knockdown; PFV, Prototype foamy
virus; LANA, Latency associated nuclear antigen; HPV, Human papilloma virus; LEDGF, Lens
epithelium-derived growth factor.
(EPS)
S3 Fig. LEDGF-hybrids retarget lentiviral integration towards a more randomizedpattern.
Genomic heat maps comparing integration site data sets obtained from HeLaP4 LEDGF/p75
KD cells overexpressing different artificial LEDGF-hybrids to genomic features. Tile color
depicting the nature of the correlation for an integration dataset with the respective genomic
feature (left) relative to matched random controls, as indicated by the colored receiver operat-
ing characteristic (ROC) curve area scale at the bottom of the panel. Statistical significance
(asterisks, p<0.001, rankedWald tests) is shown relative to (a) ΔN93-LEDGF or (b)
LEDGFBC, respectively (double dash). Columns show different data sets while rows indicate
different genomic features analyzed (described in [63]). LANA, Latency associated nuclear
antigen; HPV, Human papilloma virus; PFV, Prototype foamy virus; LEDGF, Lens epithelium-
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derived growth factor.
(EPS)
S4 Fig. LEDGF-hybrids retarget lentiviral integration towards a more randomizedpattern.
Epigenetic heat map comparing integration site data sets obtained fromHeLaP4 LEDGF/p75
depleted cells overexpressing different artificial LEDGF-hybrids to epigenetic features, gener-
ated using the INSIPID software (Bushman Lab, University of Pennsylvania). Tile color depict-
ing a positive or negative correlation to the respective epigenetic feature (10 kb windows),
relative to matched random controls, as indicated by the receiver operating characteristic
(ROC) curve area scale at the bottom of the panel. Statistical significance (asterisks,
p<0.001; rankedWald tests) is shown relative to (a) ΔN93-LEDGF or (b) LEDGFBC, respec-
tively (double dash). Significance is reached when p<0.001, compared to MRC. Columns indi-
cate different data sets while rows indicate different epigenetic features analyzed. Included
features were limited to those identified in high-throughput studies performed in HeLa and
primary CD4+ T-cells. Detailed information on epigenetic marks and their roles can be found
in [87,88]. LANA, Latency associated nuclear antigen; HPV, Human papilloma virus; PFV,
Prototype foamy virus; a; LEDGF, Lens epithelium-derived growth factor;MRC, matched ran-
dom control.
(EPS)
S5 Fig. Integration frequencynear safe harbor criteria. Fig showing the percentage HIV-
derived lentiviral vector integration frequencies near features (TSS, Oncogenes [66], miRNA
encoding regions, Transcription units and ultra conserved regions) that, when hit, are consid-
ered to be unsafe as defined in [59] (Dataset details are described in the MM section). As such
these features are used to define safe harbors as regions that fall outside these criteria. Percent-
ages depict the fraction of integrations falling within the corresponding range relative to the
criteria. The % integrations negatively associated with these 5 features is used to calculate a
safety profile. (, p-value<0.5; , p-value<0.05;, p-value<0.005, Pearsons Chi-square
compared to (a) ΔN93-LEDGF or (b) LEDGFBC control condition). TSS, Transcription start
sites; UCR, Ultra conserved regions; PFV, Prototype foamy virus; HPV, Human papilloma
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